Clearmind Medicine (CNSX:CMND) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

CMND Stoklara Genel Bakış

A clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.

Şirket hakkında

CMND temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Anlamlı bir piyasa değeri yok ( CA$5M )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 1 daha fazla risk

Clearmind Medicine Inc. Rakipler

Herbal Dispatch

CNSX:HERB

CA$4.9m

Hempalta

TSXV:HEMP

CA$4.3m

Adastra Holdings

CNSX:XTRX

CA$5.3m

Christina Lake Cannabis

CNSX:CLC

CA$4.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Clearmind Medicine
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$1.60
52 Haftanın En Yüksek Seviyesi	CA$141.00
52 Haftanın En Düşük Seviyesi	CA$1.25
Beta	1.56
11 Aylık Değişim	-16.23%
3 Aylık Değişim	-55.80%
1 Yıllık Değişim	-98.79%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	-98.31%
Halka arzdan bu yana değişim	-98.81%

Son Haberler & Güncellemeler

Recent updates

We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Nov 10

Hissedar Getirileri

	CMND	CA Pharmaceuticals	CA Pazar
7D	-14.9%	-1.8%	0.4%
1Y	-98.8%	-6.7%	24.6%

Getiri vs. Endüstri: CMND geçen yıl % -6.7 oranında getiri sağlayan Canadian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: CMND geçen yıl % 24.6 oranında getiri sağlayan Canadian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CMND's price volatile compared to industry and market?
CMND volatility
CMND Average Weekly Movement	36.1%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.1%
10% least volatile stocks in CA Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: CMND hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CMND 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 30% dan 36% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2017	n/a	Adi Zuloff-Shani	www.clearmindmedicine.com

Clearmind Medicine Inc. Temel Bilgiler Özeti

Clearmind Medicine'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CMND temel i̇stati̇sti̇kler
Piyasa değeri	CA$5.07m
Kazançlar(TTM)	-CA$11.68m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.4x

F/K Oranı

CMND aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CMND gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$8.62m
Kazançlar	-US$8.62m

Son Raporlanan Kazançlar

Oct 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.72
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

CMND uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CMND Stoklara Genel Bakış

Ödüller

Risk Analizi

Clearmind Medicine Inc. Rakipler

CNSX:HERB

CA$4.9m

TSXV:HEMP

CA$4.3m

CNSX:XTRX

CA$5.3m

CNSX:CLC

CA$4.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Recent updates

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression

Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration

Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.

Clearmind Medicine Inc. has completed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice

Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office

Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100

Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial

Clearmind Medicine Inc. Common Shares Deleted from OTC Equity

High number of new and inexperienced directors

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for Its Cocaine Addiction Treatment

Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory Board

Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as Director

Clearmind Medicine Inc. Announces CFO Changes

Clearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Clearmind Medicine Inc. and Scisparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment

Clearmind Medicine Inc. Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption

SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors

Clearmind Medicine Inc. Announces the Appointment of Two New Members to Its Scientific Advisory Board

Less than half of directors are independent

Clearmind Medicine Inc. announced that it expects to receive CAD 0.96 million in funding from Medigus Ltd.

We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn Rate

Clearmind Medicine Inc. announced that it has received CAD 6.225 million in funding

Clearmind Medicine Inc. announced that it expects to receive CAD 6 million in funding

Hissedar Getirileri